Abstract
Interleukin 12 (IL12) is a heterodimeric proinflammatory cytokine that has shown promise as an anticancer agent. However, despite encouraging results in animal models, clinical trials involving IL12 have been unsuccessful due to toxic side effects associated with its systemic administration, prompting investigation into new delivery methods to confine IL12 expression to the tumor environment. In this study we used the self-cleaving property of the 2A peptide to express both codon-optimized murine IL12 subunits (muIL12opt) as a self-processing polypeptide (muIL12opt-P2A). We cloned muIL12opt-P2A driven by different inflammation-induced lentiviral expression systems to transduce murine tumor cell lines commonly employed in syngeneic tumor models. We confirmed the inducibility of these systems in vitro and in vivo and demonstrated the successful expression of both IL12 subunits and the release of bioactive IL12 upon proinflammatory stimulation in vitro. Therefore, IL12 release driven by these inflammation-regulated expression systems might be useful not only to address the impact of IL12 expression in the tumor environment but also to achieve a local IL12 release controlled by the inflammation state of the tumor, thus avoiding toxic side effects associated with systemic administration.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ostrand-Rosenberg S . Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008; 18: 11–18.
Malmberg KJ, Ljunggren HG . Escape from immune- and nonimmune-mediated tumor surveillance. Semin Cancer Biol 2006; 16: 16–31.
Chen DS, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39: 1–10.
Vignali DA, Kuchroo VK . IL-12 family cytokines: immunological playmakers. Nat Immunol 2012; 13: 722–728.
Tahara H, Lotze MT . Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995; 2: 96–106.
Sangro B, Melero I, Qian C, Prieto J . Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573–581.
Lasek W, Zagozdzon R, Jakobisiak M . Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother 2014; 63: 419–435.
Mazzolini G, Prieto J, Melero I . Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003; 9: 1981–1991.
Freytag SO, Barton KN, Zhang Y . Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 2013; 20: 1131–1139.
Paul D, Qazilbash MH, Song K, Xu H, Sinha BK, Liu J et al. Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12). Cancer Gene Ther 2000; 7: 308–315.
Wei LZ, Xu Y, Nelles EM, Furlonger C, Wang JC, Di Grappa MA et al. Localized interleukin-12 delivery for immunotherapy of solid tumours. J Cell Mol Med 2013; 17: 1465–1474.
Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL . Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther 2013; 20: 17–24.
Tietje A, Li J, Yu X, Wei Y . MULT1E/mIL-12: a novel bifunctional protein for natural killer cell activation. Gene Ther 2014; 21: 468–475.
Melero I, Quetglas JI, Reboredo M, Dubrot J, Rodriguez-Madoz JR, Mancheno U et al. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL-12. Cancer Res 2014; 75: 497–507.
Garaulet G, Alfranca A, Torrente M, Escolano A, Lopez-Fontal R, Hortelano S et al. IL10 released by a new inflammation-regulated lentiviral system efficiently attenuates zymosan-induced arthritis. Mol Ther 2013; 21: 119–130.
van de Loo FA, de Hooge AS, Smeets RL, Bakker AC, Bennink MB, Arntz OJ et al. An inflammation-inducible adenoviral expression system for local treatment of the arthritic joint. Gene Ther 2004; 11: 581–590.
Khoury M, Adriaansen J, Vervoordeldonk MJ, Gould D, Chernajovsky Y, Bigey P et al. Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J Gene Med 2007; 9: 596–604.
Gillessen S, Carvajal D, Ling P, Podlaski FJ, Stremlo DL, Familletti PC et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol 1995; 25: 200–206.
Jalah R, Rosati M, Ganneru B, Pilkington GR, Valentin A, Kulkarni V et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem 2013; 288: 6763–6776.
Rodriguez A, Flemington EK . Transfection-mediated cell-cycle signaling: considerations for transient transfection-based cell-cycle studies. Anal Biochem 1999; 272: 171–181.
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D . Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875.
Scherr M, Battmer K, Blomer U, Ganser A, Grez M . Quantitative determination of lentiviral vector particle numbers by real-time PCR. Biotechniques 2001; 31: 520, 522, 524, passim.
Schoenhaut DS, Chua AO, Wolitzky AG, Quinn PM, Dwyer CM, McComas W et al. Cloning and expression of murine IL-12. J Immunol 1992; 148: 3433–3440.
Chaplin PJ, Camon EB, Villarreal-Ramos B, Flint M, Ryan MD, Collins RA . Production of interleukin-12 as a self-processing 2A polypeptide. J Interferon Cytokine Res 1999; 19: 235–241.
De Rose R, Scheerlinck JP, Casey G, Wood PR, Tennent JM, Chaplin PJ . Ovine interleukin-12: analysis of biologic function and species comparison. J Interferon Cytokine Res 2000; 20: 557–564.
Ryan MD, King AM, Thomas GP . Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 1991; 72: 2727–2732.
de Felipe P, Hughes LE, Ryan MD, Brown JD . Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem 2003; 278: 11441–11448.
Prussin C, Metcalfe DD . Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods 1995; 188: 117–128.
Cekic C, Day YJ, Sag D, Linden J . Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 2014; 74: 7250–7259.
Sato Y, Goto Y, Narita N, Hoon DS . Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009; 2: 205–214.
Arber C, Abhyankar H, Heslop HE, Brenner MK, Liu H, Dotti G et al. The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther 2013; 20: 958–962.
Pavlin D, Cemazar M, Sersa G, Tozon N . IL-12 based gene therapy in veterinary medicine. J Transl Med 2012; 10: 234–244.
Van der Jeught K, Bialkowski L, Daszkiewicz L, Broos K, Goyvaerts C, Renmans D et al. Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget 2015; 6: 1359–1381.
Rodriguez-Madoz JR, Prieto J, Smerdou C . Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153–163.
Triozzi PL, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE et al. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 2005; 16: 91–100.
Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH . Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705–1721.
Quetglas JI, Labiano S, Aznar MA, Bolanos E, Azpilikueta A, Rodriguez I et al. Virotherapy with a Semliki forest virus-based vector encoding IL12 synergizes with PD-1/PD-L1 blockade. Cancer Immunol Res 2015; 3: 449–454.
Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JL, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15: 457–472.
Acknowledgements
We thank Dr Filip Lim for critical reading of the manuscript and helpful discussions. We also gratefully thank Dr BK Felber for providing us with the AG250-DPmuIL12opt plasmid. AR is supported by the Spanish Ministry of Economy and Competitivity (MINECO; SAF2012–32166) and the Comunidad Autónoma de Madrid (S2010/BMD-2312). JMZ is supported by the Instituto de Salud de Carlos III (PI12/01135).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interests.
Rights and permissions
About this article
Cite this article
Lorenzo, C., Pérez-Chacón, G., Garaulet, G. et al. Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines. Cancer Gene Ther 22, 542–551 (2015). https://doi.org/10.1038/cgt.2015.53
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2015.53